Inhibition of megakaryocyte differentiation by Antibody–Drug Conjugates (ADCs) is mediated by macropinocytosis: Implications for ADC-induced thrombocytopenia

Molecular Cancer Therapeutics

Volumn 16, Issue 9, 2017, Pages 1877-1886

  Zhao, Hui ^a   Gulesserian, Sara ^a   Ganesan, Sathish Kumar ^a   Ou, Jimmy ^a   Morrison, Karen ^a   Zeng, Zhilan ^a   Robles, Veronica ^a   Snyder, Josh ^a   Do, Lisa ^a   Aviña, Hector ^a   Karki, Sher ^a   Stover, David R ^a   Doñate, Fernando ^a  

^a Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; AGS 16C3F; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; DEXTRAN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 3; FC RECEPTOR IIA; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOMETHYL AURISTATIN F; PROTEIN; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; FC RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; EVALUATION STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MEGAKARYOCYTE; PATHOGENESIS; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; BLOOD; CHEMICALLY INDUCED; CYTOLOGY; METABOLISM; PROTEIN TRANSPORT; THROMBOCYTE ACTIVATION;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BLOOD PLATELETS; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOCONJUGATES; MEGAKARYOCYTES; PINOCYTOSIS; PLATELET ACTIVATION; PROTEIN TRANSPORT; RECEPTORS, IGG; THROMBOCYTOPENIA;

EID: 85029459403     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0710     Document Type: Article

References (31)

1. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res 2013;19:22–7.
2. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–6.
3. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012;69:1229–40.
4. Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res 2014;20:15–20.
5. Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with chemotherapy and 2 or more HER2-targeted agents: results from the T-PAS expanded access study. Cancer J 2015;21:357–64.
6. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016;8:659–71.
7. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248–62.
8. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016;40:14–23.
9. Donate F, Raitano A, Morrison K, An Z, Capo L, Avina H, et al. AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res 2016;22:1989–99.
10. Thompson JA, Motzer R, Molina AM, Choueiri TK, Heath EI, Kollmannsberger CK, et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J Clin Oncol 33;15:2015.
11. McCrae K. Thrombocytopenia: Boca Raton, FL: CRC Press; 2006.
12. Liebman HA. Thrombocytopenia in cancer patients. Thromb Res 2014;133 Suppl2:S63–9.
13. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology 2015;29:282–94.
14. Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989;37: 162–90.
15. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234–41.
16. Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 2015;21:123–33.
17. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr.High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)–mediated inhibition of platelet production. Blood 2012;120:1975–84.
18. Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, et al. Understanding how the stability of the thiol-maleimide linkage impacts the pharmacokinetics of lysine-linked antibody-maytansinoid conjugates. Bioconjug Chem 2016;27:1588–98.
19. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008;19:759–65.
20. Wu Z, Markovic B, Chesterman CN, Chong BH. Characterization of Fcgamma receptors on human megakaryocytes. Thromb Haemost 1996;75:661–7.
21. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIb-beta3 outside-in integrin signaling in human platelets. Blood 2008;112: 2780–6.
22. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014;14:94–108.
23. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005–10.
24. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008;7:2517–27.
25. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23; p22p23). Leukemia 1997;11:1469–77.
26. Kerr MC, Teasdale RD. Defining macropinocytosis. Traffic 2009;10: 364–71.
27. Falcone S, Cocucci E, Podini P, Kirchhausen T, Clementi E, Meldolesi J. Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci 2006;119:4758–69.
28. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013;497:633–7.
29. Wang JT, Teasdale RD, Liebl D. Macropinosome quantitation assay. MethodsX 2014;1:36–41.
30. Ha KD, Bidlingmaier SM, Liu B. Macropinocytosis exploitation by cancers and cancer therapeutics. Front Physiol 2016;7:381.
31. Guffroy M, Falahatpisheh H, Biddle K, Kreeger J, Obert L, Walters K, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in Cynomolgus monkeys - mechanism and monitoring. Clin Cancer Res 2017;23:1760–70.